Skip to main content
main-content

01.12.2018 | Review | Ausgabe 1/2018 Open Access

Journal of Experimental & Clinical Cancer Research 1/2018

The perfect personalized cancer therapy: cancer vaccines against neoantigens

Zeitschrift:
Journal of Experimental & Clinical Cancer Research > Ausgabe 1/2018
Autoren:
Luigi Aurisicchio, Matteo Pallocca, Gennaro Ciliberto, Fabio Palombo
Wichtige Hinweise
Luigi Aurisicchio and Matteo Pallocca contributed equally.
Gennaro Ciliberto and Fabio Palombo contributed equally.

Abstract

In the advent of Immune Checkpoint inhibitors (ICI) and of CAR-T adoptive T-cells, the new frontier in Oncology is Cancer Immunotherapy because of its ability to provide long term clinical benefit in metastatic disease in several solid and liquid tumor types. It is now clear that ICI acts by unmasking preexisting immune responses as well as by inducing de novo responses against tumor neoantigens. Thanks to theprogress made in genomics technologies and the evolution of bioinformatics, neoantigens represent ideal targets, due to their specific expression in cancer tissue and the potential lack of side effects. In this review, we discuss the promise of preclinical and clinical results with mutation-derived neoantigen cancer vaccines (NCVs) along with the current limitations from bioinformatics prediction to manufacturing an effective new therapeutic approach.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

Journal of Experimental & Clinical Cancer Research 1/2018 Zur Ausgabe